Case Report

Recognizing the difference between “self” and “nonself” is a crucial role of the immune system; to regulate this recognition process, the immune system uses complex pathways, including several immune checkpoints. Recent understanding of these checkpoints, and how they affect T-cell activation, has led to therapeutic targets for cancer treatment.

The authors describe a case of an undetectable everolimus level in a patient with kidney cancer who received phenobarbital and was hospitalized because of heart failure.

Hematology oncology pharmacists should be aware of this rare and potentially devastating complication of temozolomide therapy.

To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy.
To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy.

Results 1 - 5 of 5